Immatics (IMTX) Financials: History & Chart

Immatics N.V.(IMTX)

Biotechnology · Tübingen, BW

$7.78+0.05 (+0.65%)

Delayed quote: Oct 6, 2026, 12:15 PM EDT

About Immatics N.V.

Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted immunotherapies for solid tumors, utilizing two distinct approaches: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. The company's ACTengine™ portfolio features several candidates in Phase I clinical trials. These include IMA201, designed to recognize melanoma-associated antigens 4 or 8 in solid tumor patients; IMA202, which targets melanoma-associated antigen 1 across various solid tumor types, such as squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203, aimed at preferentially expressed antigen in melanoma in adult patients with recurrent or treatment-resistant solid tumors. Additionally, IMA204, currently in preclinical stages, focuses on targeting tumor stroma cells. In its preclinical TCR Bispecifics pipeline, Immatics is advancing IMA401, which targets cancer testis antigens for solid tumor indications, and IMA402, also under investigation for solid tumor therapies. Other programs include IMA101 for cancer treatment and IMA301, an allogeneic cellular therapy candidate. Immatics has established strategic partnerships to bolster its development efforts. These include collaborations with GlaxoSmithKline Intellectual Property Development Limited for novel adoptive cell therapies across various cancer indications; MD Anderson Cancer Center for multiple T-cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC for additional novel adoptive cell therapies; and Genmab A/S to develop T-cell engaging bispecific immunotherapies for diverse cancer indications. The company's headquarters are situated in Tübingen, Germany.

Tübingen, BW

704 employees

www.immatics.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Harpreet Singh

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	48.54M	10.44M	8.79M	23.21M	6.09M	5.58M	20.10M	58.25M	56.29M
Cost of Goods Sold	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	48.54M	10.44M	8.79M	23.21M	6.09M	5.58M	20.10M	58.25M	56.29M
Gross Profit Margin	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Total Operating Expenses	311.39M	87.20M	85.12M	68.88M	70.19M	68.20M	58.35M	57.31M	55.72M
Research & Development	253.33M	71.28M	68.38M	58.31M	55.35M	53.17M	45.32M	43.33M	43.32M
Selling, General & Administrative	63.61M	15.92M	16.77M	16.05M	14.87M	15.06M	13.05M	14.00M	12.42M
Operating Income (EBIT)	-262.86M	-76.76M	-76.33M	-45.67M	-64.10M	-62.62M	-38.26M	935K	572K
Operating Margin	-541.6%	-735.0%	-867.9%	-196.8%	-1053.3%	-1121.5%	-190.4%	1.6%	1.0%
Income Before Tax (EBT)	-239.65M	-71.69M	-66.73M	-41.77M	-59.46M	-84.10M	-44.18M	44.81M	-2.62M
Interest Income	16.65M	3.75M	4.14M	4.17M	4.59M	5.02M	5.91M	7.06M	6.15M
Interest Expense	1.01M	232K	245K	261K	271K	288K	269K	240K	262K
Other Income/Expense	23.20M	5.07M	9.59M	3.90M	4.65M	-21.48M	-5.92M	43.87M	-3.19M
Net Income	-239.41M	-71.38M	-66.79M	-41.93M	-59.31M	-82.92M	-43.10M	46.46M	-9.54M
Income Tax Expense	-245K	-313K	60K	157K	-149K	-1.18M	-1.07M	-1.65M	6.92M
Net Profit Margin	-493.3%	-683.4%	-759.5%	-180.6%	-974.5%	-1485.1%	-214.5%	79.8%	-17.0%
EBITDA	-248.85M	-73.27M	-73.12M	-41.95M	-60.51M	-59.05M	-34.86M	4.12M	3.95M
EBITDA Margin	-512.7%	-701.6%	-831.4%	-180.7%	-994.2%	-1057.7%	-173.5%	7.1%	7.0%
Depreciation & Amortization	14.01M	3.49M	3.21M	3.72M	3.60M	3.57M	3.40M	3.19M	3.38M
EPS Basic	-1.84	-0.53	-0.50	-0.33	-0.49	-0.68	-0.36	0.48	-0.09
EPS Diluted	-1.84	-0.53	-0.50	-0.33	-0.49	-0.68	-0.36	0.48	-0.12
Weighted Average Basic Shares	136.68M	136.68M	134.64M	126.05M	121.56M	121.55M	121.55M	105.75M	105.88M
Weighted Average Diluted Shares	136.68M	136.68M	134.64M	126.05M	121.56M	121.55M	121.55M	106.80M	110.30M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	56.69M	161.37M	59.60M	184.92M	39.57M	38.18M	20.70M	4.31M
Cost of Goods Sold	0.00	0.00	0.00	0.00	0.00	81.95M	44.99M	38.88M
Gross Profit	56.69M	161.37M	59.60M	184.92M	39.57M	-43.77M	-24.29M	-34.56M
Gross Profit Margin	100.0%	100.0%	100.0%	100.0%	100.0%	-114.7%	-117.3%	-801.1%
Total Operating Expenses	270.49M	201.35M	171.88M	152.87M	137.81M	41.39M	57.75M	43.70M
Research & Development	215.93M	153.33M	130.97M	114.25M	99.69M	81.95M	44.99M	38.88M
Selling, General & Administrative	60.12M	48.10M	42.16M	38.65M	38.49M	41.76M	13.19M	8.77M
Operating Income (EBIT)	-213.79M	-39.99M	-112.28M	32.05M	-98.23M	-85.16M	-37.05M	-39.38M
Operating Margin	-377.1%	-24.8%	-188.4%	17.3%	-248.2%	-223.1%	-178.9%	-912.7%
Income Before Tax (EBT)	-233.08M	22.10M	-107.06M	44.98M	-106.25M	-258.78M	-36.46M	-37.03M
Interest Income	20.18M	25.89M	15.28M	2.65M	151K	685K	887K	580K
Interest Expense	1.11M	917K	917K	1.11M	644K	N/A	191K	18K
Other Income/Expense	-19.29M	62.09M	5.22M	12.93M	-8.02M	-173.62M	590K	2.35M
Net Income	-230.74M	15.76M	-104.47M	29.64M	-106.25M	-258.10M	-35.62M	-35.99M
Income Tax Expense	-2.34M	6.35M	-2.59M	15.34M	0.00	0.00	0.00	0.00
Net Profit Margin	-407.0%	9.8%	-175.3%	16.0%	-268.5%	-676.0%	-172.0%	-834.1%
EBITDA	-199.23M	-27.33M	-104.29M	39.50M	-92.25M	-82.44M	-32.73M	-36.81M
EBITDA Margin	-351.4%	-16.9%	-175.0%	21.4%	-233.1%	-215.9%	-158.1%	-853.1%
Depreciation & Amortization	14.56M	12.66M	7.98M	7.45M	5.99M	2.72M	4.32M	2.57M
EPS Basic	-1.81	0.14	-1.30	N/A	-1.68	-5.37	-0.56	-0.57
EPS Diluted	-1.81	0.14	-1.30	N/A	-1.68	-5.37	-0.56	-0.57
Weighted Average Basic Shares	122.35M	106.80M	80.55M	66.99M	62.91M	48.00M	62.91M	62.91M
Weighted Average Diluted Shares	122.35M	106.80M	80.55M	68.21M	62.91M	48.00M	62.91M	62.91M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.